A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine
Status:
Recruiting
Trial end date:
2024-12-23
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the effect of hepatic impairment on the
pharmacokinetics (PK) of emraclidine following administration of a single oral dose in
participants with mild, moderate, and severe hepatic impairment relative to matched
participants with normal hepatic function.